Acambis plc’s (" Acambis”) (LSE: ACM, NASDAQ: ACAM) programme to develop a second-generation, single-dose vaccine against Japanese encephalitis (“JE”) has achieved a major milestone with the start of pivotal Phase III trials.
Acambis plc’s (" Acambis”) (LSE: ACM, NASDAQ: ACAM) programme to develop a second-generation, single-dose vaccine against Japanese encephalitis (“JE”) has achieved a major milestone with the start of pivotal Phase III trials.
